Good report, I liked this......
The 2nd dose cohort of the Phase 1 trial was completed in December, with all patients advancing past the
28 day follow up period with no dose-limiting toxicities.
The study has advanced to the 3rd dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an
increased total dose of 220 X 106 CLTX CAR T cells.
Good report, I liked this......The 2nd dose cohort of the Phase...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |